AxoGen, Inc. (AXGN)
NASDAQ$17.25
Market Cap
$764.93M
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
471 of 924
Rank in Industry
58 of 118
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AXGN Insider Trading Activity
AXGN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $536,109 | 5 | 100 |
Related Transactions
| DeVinney Erick Wayne | Chief Innovation Officer | 0 | $0 | 1 | $35,159 | $-35,159 |
| Donovan Michael Patrick | VP Operations | 0 | $0 | 1 | $46,333 | $-46,333 |
| Scopelianos Angelo | Chief R&D Officer | 0 | $0 | 1 | $52,846 | $-52,846 |
| Wendell Amy McBride | director | 0 | $0 | 1 | $100,100 | $-100,100 |
| Zaderej Karen L. | CEO | 0 | $0 | 1 | $301,670 | $-301,670 |
About AxoGen, Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM …
Insider Activity of AxoGen, Inc.
Over the last 12 months, insiders at AxoGen, Inc. have bought $0 and sold $536,109 worth of AxoGen, Inc. stock.
On average, over the past 5 years, insiders at AxoGen, Inc. have bought $188,940 and sold $2.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $62,240 was made by Wendell Amy McBride (director) on 2023‑09‑06.
List of Insider Buy and Sell Transactions, AxoGen, Inc.
| 2025-03-03 | Sale | Wendell Amy McBride | director | 5,000 0.012% | $20.02 | $100,100 | -9.44% | |
| 2024-03-21 | Sale | Zaderej Karen L. | CEO | 39,280 0.091% | $7.68 | $301,670 | +71.06% | |
| 2024-03-21 | Sale | DeVinney Erick Wayne | Chief Innovation Officer | 4,578 0.0106% | $7.68 | $35,159 | +71.06% | |
| 2024-03-21 | Sale | Scopelianos Angelo | Chief R&D Officer | 6,881 0.0159% | $7.68 | $52,846 | +71.06% | |
| 2024-03-21 | Sale | Donovan Michael Patrick | VP Operations | 6,033 0.014% | $7.68 | $46,333 | +71.06% | |
| 2024-03-07 | Sale | Freitag Gregory Gene | director | 25,000 0.0581% | $9.00 | $225,000 | +42.46% | |
| 2024-03-07 | Sale | Donovan Michael Patrick | VP Operations | 36,310 0.0826% | $8.81 | $319,891 | +42.46% | |
| 2023-12-11 | Sale | MARIANI PETER J | EVP & Chief Financial Officer | 12,500 0.0291% | $7.50 | $93,809 | +19.60% | |
| 2023-09-06 | Wendell Amy McBride | director | 10,000 0.0235% | $6.22 | $62,240 | +19.43% | ||
| 2023-08-23 | Burke William P. Mr. | director | 10,000 0.0234% | $6.56 | $65,600 | +9.66% | ||
| 2023-08-16 | NEELS GUIDO J | director | 10,000 0.0252% | $6.11 | $61,100 | +24.78% | ||
| 2023-06-01 | Sale | Freitag Gregory Gene | director | 41,980 0.0994% | $8.71 | $365,780 | -18.29% | |
| 2023-05-23 | Sale | Freitag Gregory Gene | director | 7,468 0.0176% | $9.23 | $68,899 | -21.11% | |
| 2023-02-01 | Sale | MARIANI PETER J | EVP & Chief Financial Officer | 14,550 0.0348% | $9.36 | $136,188 | -11.30% | |
| 2023-01-31 | Sale | MARIANI PETER J | EVP & Chief Financial Officer | 14,320 0.0343% | $9.55 | $136,756 | -12.99% | |
| 2023-01-30 | Sale | MARIANI PETER J | EVP & Chief Financial Officer | 14,111 0.0334% | $9.69 | $136,736 | -15.31% | |
| 2023-01-27 | Sale | MARIANI PETER J | EVP & Chief Financial Officer | 20,940 0.0495% | $10.16 | $212,750 | -19.34% | |
| 2022-11-16 | Sale | MARIANI PETER J | EVP & Chief Financial Officer | 10,649 0.027% | $11.88 | $126,510 | -24.30% | |
| 2022-11-14 | Sale | Freitag Gregory Gene | director | 13,000 0.0339% | $12.74 | $165,620 | -27.03% | |
| 2022-11-08 | Sale | Freitag Gregory Gene | director | 13,000 0.0337% | $12.50 | $162,500 | -25.70% |
Total: 129
*Gray background shows transactions not older than one year
Insider Historical Profitability
12.86%
| Zaderej Karen L. | CEO | 1124565 2.536% | $19.4M | 9 | 8 | +15.63% |
| Wendell Amy McBride | director | 97899 0.2208% | $1.69M | 4 | 1 | <0.0001% |
| Mandato Joseph M | director | 1226773 2.7665% | $21.16M | 1 | 4 | +61.29% |
| Hopfenspirger Larry | 10 percent owner | 426066 0.9608% | $7.35M | 1 | 0 | |
| Gold Mark Stephen | director | 348761 0.7865% | $6.02M | 5 | 1 | +18.2% |
*Gray background shows insiders who have made transactions during last year
AXGN Institutional Investors: Active Positions
| Increased Positions | 80 | +40.82% | 4M | +10% |
| Decreased Positions | 84 | -42.86% | 4M | -11.45% |
| New Positions | 35 | New | 1M | New |
| Sold Out Positions | 18 | Sold Out | 544,846 | Sold Out |
| Total Postitions | 192 | -2.04% | 36M | -1.45% |
AXGN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| First Light Asset Management, Llc | $90,181.00 | 10.24% | 4.51M | +416,499 | +10.18% | 2024-12-31 |
| Blackrock, Inc. | $68,049.00 | 7.73% | 3.4M | -11,931 | -0.35% | 2024-12-31 |
| Soleus Capital Management, L.P. | $59,148.00 | 6.72% | 2.96M | -50,000 | -1.66% | 2024-12-31 |
| Morgan Stanley | $48,634.00 | 5.52% | 2.43M | -469,947 | -16.2% | 2024-12-31 |
| Vanguard Group Inc | $48,543.00 | 5.51% | 2.43M | +139 | +<0.01% | 2024-12-31 |
| Arrowmark Colorado Holdings Llc | $44,998.00 | 5.11% | 2.25M | -26,671 | -1.17% | 2024-12-31 |
| Geode Capital Management, Llc | $20,150.00 | 2.29% | 1.01M | -3,512 | -0.35% | 2024-12-31 |
| State Street Corp | $19,322.00 | 2.2% | 965,607 | +68,933 | +7.69% | 2024-12-31 |
| Driehaus Capital Management Llc | $19,098.00 | 2.17% | 954,439 | +595,579 | +165.96% | 2024-12-31 |
| Dafna Capital Management Llc | $16,946.00 | 1.93% | 846,882 | -89,012 | -9.51% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.